Latest Trials Latest NewsFAQ

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity

Phase 4

Completed

Conditions: Obesity

Interventions: Other: Weight Management Program (WMP)
Drug: Medication for chronic weight management (Rx)

First Posted Date: 2019-01-10

Last Posted Date: 2022-11-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT03799198

Locations: 🇺🇸
Novo Nordisk Investigational Site, Cleveland, Ohio, United States

A Study of People With Type 2 Diabetes Who Have Diseases That Affect the Heart and Blood Vessels. The Study Will Also Look at the Treatment of a Group of These People in Hospitals in Portugal

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2019-01-09

Last Posted Date: 2020-11-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 730

Registration Number: NCT03797885

Locations: 🇵🇹
Novo Nordisk Investigational Site, Viseu, Portugal

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: NNC0148-0287
Drug: NNC0148-0287sema
Drug: Semaglutide

First Posted Date: 2018-12-28

Last Posted Date: 2024-11-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 30

Registration Number: NCT03789578

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Phase 1

Completed

Conditions: Obesity
Overweight

Interventions: Drug: NNC0174-0833
Drug: Placebo (NNC0174-0833)

First Posted Date: 2018-12-26

Last Posted Date: 2019-06-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 66

Registration Number: NCT03787225

Locations: 🇺🇸
Novo Nordisk Investigational Site, Glendale, California, United States

An International Survey of the Occurrence of Diseases That Affects the Heart and Blood Vessels Among People With Type 2 Diabetes

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2018-12-26

Last Posted Date: 2023-06-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2275

Registration Number: NCT03786406

Locations: 🇮🇹
Novo Nordisk Investigational Site, Savigliano (CN), Italy

A Research Study, Looking at How Tresiba® Works in People With Type 2 Diabetes in Local Clinical Practice in Saudi Arabia

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec

First Posted Date: 2018-12-24

Last Posted Date: 2021-06-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 597

Registration Number: NCT03785522

Locations: 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: insulin icodec
Drug: Insulin glargine U100

First Posted Date: 2018-12-06

Last Posted Date: 2021-03-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT03766854

Locations: 🇯🇵
Novo Nordisk Investigational Site, Fukuoka, Japan

A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (insulin 287)
Drug: Insulin icodec
Drug: Metformin
Drug: Dipeptidyl peptidase-4 inhibitors
Drug: Placebo (insulin glargine)
Drug: Insulin glargine

First Posted Date: 2018-11-23

Last Posted Date: 2021-04-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 247

Registration Number: NCT03751657

Locations: 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia

RESILIENT: A Research Study, Looking at How Ryzodeg® Works in People With Type 2 Diabetes in Local Clinical Practice in Japan

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Degludec/Insulin Aspart

First Posted Date: 2018-11-19

Last Posted Date: 2019-12-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 246

Registration Number: NCT03745157

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Kanagawa, Japan

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Conditions: Haemophilia B

Interventions: Drug: Nonacog beta pegol

First Posted Date: 2018-11-19

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT03745924

Locations: 🇩🇪
Vivantes Klinikum am Friedrichshain - Innere Medizin - Angiologie und Hämostaseologie, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn, Germany
🇦🇹
AKH - Klin. Abt. f. Haematologie u. Haemostaseologie, Wien, Austria

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy